Replimune Group (NASDAQ:REPL) Upgraded by JPMorgan Chase & Co. to Neutral Rating

JPMorgan Chase & Co. upgraded shares of Replimune Group (NASDAQ:REPL) from an underweight rating to a neutral rating in a research report report published on Monday, Marketbeat.com reports. JPMorgan Chase & Co. currently has $11.00 price objective on the stock.

Other analysts also recently issued research reports about the stock. Jefferies Financial Group reduced their price objective on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Barclays cut shares of Replimune Group from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $17.00 to $3.00 in a report on Wednesday, July 23rd. Piper Sandler lowered shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a report on Tuesday, July 22nd. HC Wainwright reissued a “neutral” rating on shares of Replimune Group in a research report on Monday, September 8th. Finally, BMO Capital Markets downgraded Replimune Group from an “outperform” rating to an “underperform” rating and reduced their target price for the company from $27.00 to $2.00 in a research note on Wednesday, July 23rd. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Replimune Group presently has a consensus rating of “Hold” and a consensus target price of $11.00.

Replimune Group Trading Up 98.7%

Replimune Group stock opened at $8.94 on Monday. The business has a 50 day moving average price of $5.11 and a two-hundred day moving average price of $7.28. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The stock has a market cap of $697.86 million, a price-to-earnings ratio of -2.76 and a beta of 0.42.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). As a group, equities analysts forecast that Replimune Group will post -2.97 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Emily Luisa Hill sold 9,154 shares of Replimune Group stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the transaction, the chief financial officer owned 134,368 shares in the company, valued at $721,556.16. This trade represents a 6.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Replimune Group by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company’s stock valued at $37,372,000 after buying an additional 237,185 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after acquiring an additional 33,574 shares during the period. MPM Bioimpact LLC grew its position in shares of Replimune Group by 3.9% in the first quarter. MPM Bioimpact LLC now owns 987,036 shares of the company’s stock valued at $9,624,000 after purchasing an additional 37,036 shares in the last quarter. Parkman Healthcare Partners LLC raised its stake in shares of Replimune Group by 9.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company’s stock valued at $9,266,000 after purchasing an additional 80,640 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Replimune Group by 20.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after purchasing an additional 119,145 shares during the period. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.